Manufacturing Psychedelic Medicines to Unlock Neurologic Potential
Manufacturing Psychedelic Medicines to Unlock Neurologic Potential
Team
Luke McFarlane
CEO, Managing Director
>17 years experience in investment management, equity research and corporate finance
Portfolio manager at Balyasny Asset Management and Millennium Management
Investment analyst at Platinum Asset Management
Experience with Macquarie Capital and BDO in equity research and corporate finance
Founder of Mountain Ash Investment Management and co-Founder of Ezel.Life
BS Finance from La Trobe University
Mario Gattino
Director
20 years at Pfizer, 4-years as CEO of the Central-Eastern Europe and three years as COO of Northern Europe.
Held senior executive roles at Respiri, Mallinckrodt Pharmaceuticals ANZ and MG Squared Ventures.
MBA, GD, BSc, Senior Executive Program at Harvard Business School,,
Successful career focused on driving growth, product commercialization and integrating business transformations across North America, Europe, Asia Pacific and Latin America.
Mark Hestermann
Chief Operating Officer
>12 years experience as an ethnobotanical and anthropological researcher
5+ years founding, directing and managing start-ups from idea through pre-seed, seed, and series A
Inventor on two PCT patent applications
BS Biotechnology, Molecular Biology major, RMIT University
Founder of Natural MedTech
Mark Riccio
Director
>20 years experience in private equity, investment banking and structured finance
Director in Macquarie’s Commodities and Global Markets Group
Director at PE firm Denham Capital
Experience with Merrill Lynch and Invesco Funds in investment banking and asset management respectively
Co-Founder of TSX-listed Nova Royalty and Natural Medtech
Multiple prior board memberships at private companies
MBA from University of Texas, Austin and BS Finance and Economics from University of Colorado, Boulder
CFA Charter holder
OUR BUSINESS
We are focused on substantial market opportunities
Production
Active Pharmaceutical Ingredient (API)
Developing patentable bioproduction pathways for low-cost psychedelic manufacturing
Substantial intellectual property (“IP”) identified, with provisional patents filed
IP unlocks unique pathways to multiple psychedelic tryptamine derivatives
Production of GMP psilocybin for TGA and FDA clinical trials and Authorized prescriber scheme
Market Opportunity
Psychedelic molecule production expected to be a US$7Bn market by 20261
Psilocybin market size is estimated to reach $1.2 billion by 20272
Drug Development
Developing proprietary formulations focused on neuro-regeneration and neurodevelopment
Focused on commercially significant and overlooked unmet needs with large potential IP opportunities
The global neuro-degenerative disease market is expected to reach US$67.5 billion by 20273
Between 15% to 20% of children have neurodevelopmental disorders4
An ethical and sustainable approach to neurological disorders
ESG is a core consideration in NMT’s strategy
Environmental
Lower carbon footprint and byproduct waste versus synthetic production
Raise awareness of the illegal harvesting of endangered flora with psychedelic molecule bioproduction
Sponsor efforts to regenerate rare and threatened native flora associated with psychedelic molecules (i.e Acacia)
Social
Raise awareness of neurological issues and educate on the advances in psychedelic research and regulation advances
Develop curative treatments to reduce reliance on traditional pharmaceuticals that manage symptoms
An ethical and sustainable approach to neurological disorders
ESG is a core consideration in NMT’s strategy
Enviromental
Lower carbon footprint and byproduct waste versus synthetic production
Raise awareness of the illegal harvesting of endangered flora with psychedelic molecule bioproduction
Sponsor efforts to regenerate rare and threatened native flora associated with psychedelic molecules (i.e Acacia)
Social
Raise awareness of neurological issues and educate on the advances in psychedelic research and regulation advances
Develop curative treatments to reduce reliance on traditional pharmaceuticals that manage symptoms
resources
Natural MedTech appoints former Pfizer Executive to the Board of Directors
Single-dose psilocybin-assisted therapy in major depressive disorder (MDD)
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Ayahuasca-assisted Therapy for addiction: Results from a Preliminary Observational Study in Canada
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Psychedelic medicines for mood disorders current evidence and clinical considerations
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
CONTACT
Subscribe to our newsletter
We’d love
to hear from you
info@naturalmedtech.com
Contact us
CONTACT
We’d love to hear from you
info@naturalmedtech.com
Subscribe to our newsletter
Contact us
Acknowledgement of Country
We acknowledge the Traditional Owners of the unceded land where we work and live. We pay our respects to Elders past, present and emerging. We celebrate the stories, culture and traditions of Aboriginal and Torres Strait Islanders of all communities who work and live on this land.
© 2022 by Natural MedTech Pty Ltd, Australia all rights reserved.
Web by HUUD Solutions